USA: Federal Pain Advisory Committee Appoints Headache Advocate
Congratulations to Cathy Glaser, founder and president of the Migraine Research Foundation, who was recently appointed to a federal advisory committee focused on pain disorders.
The Interagency Pain Research Coordinating Committee (IPRCC) was created under the US Department of Health and Human Services (HHS) with the goals of collecting information about pain diseases and disorders and their treatments, and to make recommendations to federal agencies on how to more efficiently fight pain disorders.
The committee is made up of seven federal members, six from the scientific and medical community, and six public members. Up until this point, there have been not been public members focused on headache disorders (migraine or anything else), in spite of the prevalence of headache disorders.
Cathy will bring her years of experience with the Migraine Research Foundation, her interaction with doctors researchers, and specialists in the USA, as well as her personal family experience with migraine to the committee.
Feel free to congratulate Cathy! Hopefully there will be a renewed focus and renewed research on pain conditions including migraine and headache in the year ahead.
Check the link in the sidebar to support the migraine research through the MRF!

This was the Nurofen line, including Nurofen Period Pain, Nurofen Migraine Pain, Nurofen Tension Headache – all products that appeared to be specially formulated for a specific thing.
Several years ago the story came out of a woman who had been suffering from monthly migraine attacks. At one point she was diagnosed with bilateral ocular hypertension, and started taking eye drops (a timolol maleate solution). She didn’t have another migraine attack – and
But Teva is pushing ahead with a completely new medication, currently known by the catchy name TEV-48125. TEV-48125 is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), one of many similar medications being tested now.
